Mankind: A stable outlook 💡
Seeing the guidance , execution of Cupid and Anondita Medicare Clearly any investor will be in either the king or challenger.
Mankind fits no where near.❗
Mankind Guidance : " Top line will be double digit , better than last Yr"
Nothing explosive , reading that itself says 👉 we are tired .
Margin expansion ~ marginally possible. from 25.4 to 👉25.5 to 26.5
Mankind , although having the Brand name, is no where in the condom race now , their focus has shifted to
🔹Prescription pharna
🔹Chronic therapies
🔹Speciality products and 🔹BSV(acquisition)
🔹GLP1 opportunity
Mankind is that big largecap with low debt, strong cash flow generation , stable outlook , all ratios perfect 👉
-ve working capital days 🔥
but dont ask for high growth.